Rare Cancer Continuing Medical Education

Categorized in -

NORD partners with Platform Q Health to provide accredited online CME courses for healthcare providers. This online platform allows us to reach a large number of learners with accessible, engaging digital courses. We feature top medical specialists, member advocacy organizations, rare disease patients and Centers of Excellence. We provide insightful outcomes to demonstrate the effectiveness of each educational program.

NORD and Platform Q health are proud to feature ongoing courses about Rare Cancers as an important part of our CME offerings. These courses are available for credit for one year following their publication. Check out some of the past and present CME sessions on Rare Cancer conditions below.

Available for CME credit now:

Refining management of classical hodgkin lymphoma: what's on the horizon for pediatric management and aya survivorship
Hodgkin’s Lymphoma: “Refining Management of Classical Hodgkin Lymphoma: What’s on the Horizon for Pediatric Management and AYA Survivorship.”


The following sessions can be viewed, but are no longer available for CME credit and the content is current as of the published date below:

“Improving Quality of Life with Treatment Approaches in Graft versus Host Disease” (published 6/9/2022)

AL Amyloidosis: “A Rare Blood Disorder with Multi-Organ Complications” (published 4/20/2022)

Waldenström’s Macroglobulinemia: “Systemic Therapy for Symptomatic Patients with Waldenström’s Macroglobulinemia” (published 6/1/2022)

Paroxysmal Nocturnal Hemoglobinuria (PNH): “New Treatment Options for the Paroxysmal Nocturnal Hemoglobinuria (PNH) Community” (published 4/29/2022)

Cold Agglutinin Disease (CAD): “Impact of a Rare Anemia and the Promise of New Therapies” (published 4/29/2022)

T-Cell Lymphomas: “CD30‐Targeted Treatment Approaches for Patients with PTCL and CTCL” (published 8/17/2022)

Explore all of NORD’s rare disease CME content and sign up for updates here.